In response to increasing pressure, the US Food and Drug Administration (FDA) is re-examining its requirement for animal tests to be performed for products under its jurisdiction. A story in Chemical & Engineering Newsan independent news outlet of the American Chemical Society, explains that some alternative technologies that do not involve the use of animals could even improve the ability to predict human risk and efficacy for many drugs.
Although animal models have been critical in bringing new therapies to market, this type of testing raises ethical concerns, says Senior Correspondent Britt E. Erickson. In addition, animals aren’t identical to humans, and results from non-human studies can lead researchers astray. Different species absorb and metabolize drugs differently, so a drug could “fail” in mice or rats, but work well in humans, or vice versa.
Historically, FDA has only allowed alternatives to animal studies in a handful of cases, but the tide is turning. In a June 14 meeting with its Science Board, FDA discussed nonanimal approaches that could replace, reduce and refine testing for regulatory purposes. The agency’s new alternative methods (NAM) group explained that new technologies, such as microphysiological systems in combination with cellular and computational methods, have the potential to provide better results and move products to the marketplace faster. FDA is considering putting these technologies through their paces in a qualification process, which would mean that developers would not have to re-validate tools that have gone through this rigorous procedure. To fund these efforts, FDA is asking Congress for $5 million for its NAMs initiative in fiscal 2023. And language in bills to reauthorize FDA user fees would allow the agency to consider alternative technologies for preclinical drug testing, meaning it would no longer have to require animal studies.
For more of the latest research news, register for our upcoming meeting, ACS Fall 2022. Journalists and public information officers are encouraged to apply for complimentary press registration by completing this form.
The American Chemical Society (ACS) is a nonprofit organization chartered by the US Congress. ACS’ mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and all its people. The Society is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world’s scientific knowledge. ACS’ main offices are in Washington, DC, and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact firstname.lastname@example.org.
Follow us: Twitter | Facebook | LinkedIn | Instagram
Chemical & Engineering News
US FDA seeks to slash animal testing
Article Publication Date
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.